BRPI0519661A2 - uso de agonistas de ppar para o tratamento da falÊncia cardÍaca congestiva - Google Patents
uso de agonistas de ppar para o tratamento da falÊncia cardÍaca congestivaInfo
- Publication number
- BRPI0519661A2 BRPI0519661A2 BRPI0519661-2A BRPI0519661A BRPI0519661A2 BR PI0519661 A2 BRPI0519661 A2 BR PI0519661A2 BR PI0519661 A BRPI0519661 A BR PI0519661A BR PI0519661 A2 BRPI0519661 A2 BR PI0519661A2
- Authority
- BR
- Brazil
- Prior art keywords
- heart failure
- congestive heart
- ppar agonists
- treat congestive
- treat
- Prior art date
Links
- 206010007559 Cardiac failure congestive Diseases 0.000 title abstract 4
- 206010019280 Heart failures Diseases 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title abstract 3
- 101150014691 PPARA gene Proteins 0.000 title 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04029946A EP1671633A1 (en) | 2004-12-17 | 2004-12-17 | Use of PPAR agonists for the treatment of congestive heart failure |
| PCT/EP2005/013046 WO2006063715A1 (en) | 2004-12-17 | 2005-12-06 | Use of ppar agonists for the treatment of congestive heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0519661A2 true BRPI0519661A2 (pt) | 2009-03-03 |
Family
ID=34927823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519661-2A BRPI0519661A2 (pt) | 2004-12-17 | 2005-12-06 | uso de agonistas de ppar para o tratamento da falÊncia cardÍaca congestiva |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7601863B2 (enExample) |
| EP (2) | EP1671633A1 (enExample) |
| JP (1) | JP2008524129A (enExample) |
| KR (1) | KR20070086332A (enExample) |
| CN (1) | CN101072557A (enExample) |
| AR (1) | AR051723A1 (enExample) |
| AT (1) | ATE498400T1 (enExample) |
| AU (1) | AU2005315920A1 (enExample) |
| BR (1) | BRPI0519661A2 (enExample) |
| CA (1) | CA2590391A1 (enExample) |
| DE (1) | DE602005026443D1 (enExample) |
| IL (1) | IL183810A0 (enExample) |
| MX (1) | MX2007006678A (enExample) |
| MY (1) | MY141010A (enExample) |
| TW (1) | TW200635584A (enExample) |
| WO (1) | WO2006063715A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399777B2 (en) | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
| PL3523283T3 (pl) | 2016-10-05 | 2021-12-13 | Mitobridge, Inc. | Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101070316A (zh) * | 1999-04-28 | 2007-11-14 | 萨诺费－阿文蒂斯德国有限公司 | 作为ppar受体配体的二芳基酸衍生物 |
| IL160556A0 (en) * | 2001-08-31 | 2004-07-25 | Aventis Pharma Gmbh | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators |
| WO2004082621A2 (en) * | 2003-03-15 | 2004-09-30 | Bethesda Pharmaceuticals, Inc. | Novel ppar agonists, pharmaceutical compositions and uses thereof |
| US6989462B2 (en) * | 2003-03-25 | 2006-01-24 | Sanofi-Aventis Deutschland Gmbh | Synthesis of 2-chloromethyl-6-methylbenzoic ester |
| US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
-
2004
- 2004-12-17 EP EP04029946A patent/EP1671633A1/en not_active Withdrawn
-
2005
- 2005-12-06 CN CNA2005800416904A patent/CN101072557A/zh active Pending
- 2005-12-06 CA CA002590391A patent/CA2590391A1/en not_active Abandoned
- 2005-12-06 WO PCT/EP2005/013046 patent/WO2006063715A1/en not_active Ceased
- 2005-12-06 AT AT05824351T patent/ATE498400T1/de not_active IP Right Cessation
- 2005-12-06 MX MX2007006678A patent/MX2007006678A/es not_active Application Discontinuation
- 2005-12-06 EP EP05824351A patent/EP1827425B1/en not_active Expired - Lifetime
- 2005-12-06 BR BRPI0519661-2A patent/BRPI0519661A2/pt not_active IP Right Cessation
- 2005-12-06 AU AU2005315920A patent/AU2005315920A1/en not_active Abandoned
- 2005-12-06 DE DE602005026443T patent/DE602005026443D1/de not_active Expired - Lifetime
- 2005-12-06 KR KR1020077013671A patent/KR20070086332A/ko not_active Withdrawn
- 2005-12-06 JP JP2007545894A patent/JP2008524129A/ja not_active Withdrawn
- 2005-12-15 AR ARP050105284A patent/AR051723A1/es not_active Application Discontinuation
- 2005-12-15 TW TW094144376A patent/TW200635584A/zh unknown
- 2005-12-16 MY MYPI20055943A patent/MY141010A/en unknown
-
2007
- 2007-06-10 IL IL183810A patent/IL183810A0/en unknown
- 2007-06-14 US US11/762,799 patent/US7601863B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7601863B2 (en) | 2009-10-13 |
| WO2006063715A1 (en) | 2006-06-22 |
| DE602005026443D1 (de) | 2011-03-31 |
| EP1827425B1 (en) | 2011-02-16 |
| EP1827425A1 (en) | 2007-09-05 |
| KR20070086332A (ko) | 2007-08-27 |
| AR051723A1 (es) | 2007-01-31 |
| TW200635584A (en) | 2006-10-16 |
| MX2007006678A (es) | 2007-08-14 |
| CN101072557A (zh) | 2007-11-14 |
| MY141010A (en) | 2010-02-25 |
| EP1671633A1 (en) | 2006-06-21 |
| US20080039512A1 (en) | 2008-02-14 |
| IL183810A0 (en) | 2007-10-31 |
| AU2005315920A1 (en) | 2006-06-22 |
| JP2008524129A (ja) | 2008-07-10 |
| CA2590391A1 (en) | 2006-06-22 |
| ATE498400T1 (de) | 2011-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
| ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
| NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
| GEP20084499B (en) | USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE | |
| EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
| HRP20090281T1 (hr) | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti | |
| NO20075068L (no) | Lipocalinprotein | |
| NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
| NO20070247L (no) | Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase | |
| NO20074824L (no) | Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter | |
| DE602004022982D1 (de) | Verwendung von treprostinil zur verbesserung der nierenfunktion | |
| MY145340A (en) | Milnacipran for the long-term treatment of fibromyalgia syndrome | |
| DK2026803T3 (da) | Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf | |
| UY28931A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| NO20055649L (no) | Substituert dihydrokinazolin med antiviale egenskaper | |
| HRP20090498T1 (hr) | Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja | |
| BRPI0416268A (pt) | composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla | |
| DK1423384T3 (da) | Pyridinderivater som Raf kinaseinhibitorer | |
| IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| EA200701845A1 (ru) | Рофлумиласт для лечения сахарного диабета | |
| EA200400235A1 (ru) | Комбинированная терапия для лечения рака | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| PT2056805E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A. ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2203 DE 26/03/2013. |